Maria Kvasova

Dr. Maria Kvasova

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2021 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
ATA.A. Tarasova
A.A. Tarasova
MKM.P. Kostinov
M.P. Kostinov
MKMaria Kvasova
Maria Kvasova
The COVID-19 pandemic has had a huge impact on health care, economy and society around the world. At this stage of time, the cohort of school-age children from 7 to 14 years old has the highest number of positive tests for coronavirus infection, as well as an aggravation of the course of COVID-19 in the pediatric population. To stop the increase in cases of severe forms of infection, hospitalization and deaths, mass vaccination is required, including among the child population. Several vaccines against SARS-CoV-2 have been approved and used in children and adolescents worldwide, and a clinical trial of a domestic drug is being completed in Russia. The tactics of vaccination of children with chronic diseases are proposed.

18 February 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
МKМikhail Petrovich Kostinov
Мikhail Petrovich Kostinov
MKMaria Kvasova
Maria Kvasova
ATA.A. Tarasova
A.A. Tarasova
EKE.M. Kozlova
E.M. Kozlova
ENE.G. Novopoltseva
E.G. Novopoltseva
Aim of the study: to discuss available information on vaccination of pregnant and breastfeeding women against COVID-19. Pregnant women with SARS-CoV-2 infection are at high risk of developing severe COVID-19 and adverse outcomes due to increased rates of preterm birth, caesarean section, and neonatal admissions to the intensive care unit. Concomitant chronic diseases increase the number of maternal and fetal complications. Taking into account the passive immunization of the newborn by transplacental transfer of maternal protective antibodies into the fetus and newborn blood circulation and then through breast milk, the role of vaccination in pregnant and breastfeeding women increases. Conclusions: after an individual risk-benefit assessment, COVID-19 vaccine should be recommended for pregnant and breastfeeding women.

15 September 2022 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
ATA. А. Tarasova
A. А. Tarasova
МKМikhail Petrovich Kostinov
Мikhail Petrovich Kostinov
VMV. V. Mescheriakova
V. V. Mescheriakova
MKMaria Kvasova
Maria Kvasova
TST. A. Smirnova
T. A. Smirnova
Relevance. To date, there is ample evidence that diabetes mellitus (DM) and obesity are predictors of a severe course and adverse outcome of COVID-19. The SARS-CoV-2 virus is known to have deleterious effects on the pancreas, exacerbating insulin resistance The SARS-CoV-2 virus is known to have deleterious effects on the pancreas, exacerbating insulin resistance. Long-term data have been accumulated regarding pneumococcal infection and influenza, both of which are severe in patients with diabetes and obesity. The aim is to analyze scientific publications on the problems of vaccinating patients with diabetes and obesity against SARS-CoV-2, pneumococcal infection, and influenza. Conclusions. Vaccination against COVID-19 in patients with DM and obesity is an effective preventive measure. Experience with vaccination against COVID-19 using the following vaccines: Moderna mRNA-1273, Pfizer BioNTech, BNT162b2, AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience, Sputnik V showed similar safety and efficacy profiles among obese and DM patients and those at risk. Researchers in numerous publications have emphasized the importance of routine vaccination for people living with diabetes amid a pandemic of a new coronavirus infection. Researchers in numerous publications have emphasized the importance of routine vaccination for people living with diabetes in the face of a new coronavirus pandemic. Analysis of the literature reviewed in this review suggests that vaccination against SARS-CoV-2, especially for those at risk, will be an intensive area of research in the coming years and that vaccination against coronavirus infection is likely to be routine for people with diabetes and obesity.

8 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MKMikhail Petrovich Kostinov
Mikhail Petrovich Kostinov
MKMaria Kvasova
Maria Kvasova
ATAlla Anatolievna Tarasova
Alla Anatolievna Tarasova
AVAnna Vlasenko
Anna Vlasenko
EKElena Vladimirovna Kolbasina
Elena Vladimirovna Kolbasina
EFElena Petrovna Foshina
Elena Petrovna Foshina
Patients with diabetes mellitus face a significantly higher risk of severe influenza and its complications. The purpose of this study was to investigate the immunogenicity of the trivalent immunoadjuvanted subunit influenza vaccine in children with type 1 diabetes (T1D) over two consecutive seasons.Methods: A prospective non-randomized study during 2 epidemic seasons included 146 children with T1D at the age of 12.0 (9.0-14.0) years; the main group consisted of 81 patients vaccinated against influenza, the control group included 65 unvaccinated children. Antibody (Ab) levels to influenza viruses were evaluated using the hemagglutination inhibition assay before vaccination, one month and 12 months after vaccination.Results: Over two seasons, vaccinated children with T1D demonstrated a significant increase in Ab against all three vaccine strains 1 month post-vaccination, irrespective of their initial specific Ab levels. Differences in the persistence of antibodies 12 months post-vaccination were observed between children initially seronegative for A/H1N1 and A/H3N2 strains, who exhibited lower antibodies levels and fold increases, and those initially seropositive. Vaccinated seropositive children experienced significant post-vaccination Ab increases, surpassing levels in initially seronegative patients. Regardless of the epidemiological season, vaccination significantly increased the chance of achieving a seroprotective Ab level within one month for the A/H1N1 strain by 4.7 [2.9-9.7] (χ²M-H = 16.4, p < 0.001), for the A/H3N2 strain by 15.8 [5.9-41.4] (χ²M-H = 44.0, p < 0.001), and for strain B by 14.8 [6.5-33.6] (χ²M-H = 46.2, p < 0.001). Twelve months post-vaccination, Ab persistence was highest for the B strain, with levels 7.2 [3.2–16] times higher than in unvaccinated children, regardless of the season. Persistence of antibodies to the A/H1N1 strain was season-dependent (lower in the 2015-2016 season) and 2.5 [1.3-5] times higher than in unvaccinated children (χ²M-H = 6.5, p = 0.01). Antibodies persistence to the A/H3N2 strain did not differ significantly between vaccinated and unvaccinated groups (1.0 [0.5-2.3], χ²M-H = 0.02, p = 0.89).Conclusion: Administration of the trivalent immunoadjuvanted subunit influenza vaccine in children with T1D resulted in the formation of postvaccination Ab, meeting the Committee for Proprietary Medicinal Products (CPMP) immunogenicity criteria regardless of vaccination history.

14 February 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
МKМikhail Petrovich Kostinov
Мikhail Petrovich Kostinov
AKAristitsa Kostinova
Aristitsa Kostinova
SISofia Iushkova
Sofia Iushkova
LGLilya Solomonovna Gladkova
Lilya Solomonovna Gladkova
AVAnna Vlasenko
Anna Vlasenko
АKАnton Kostinov
Аnton Kostinov
Background: SARS-CoV-2 infection has raised concerns about altered immune responses, creating a need to evaluate influenza vaccine performance in the post-COVID period. This study aimed to compare the immunogenicity and safety of a quadrivalent inactivated subunit adjuvanted influenza vaccine in adults aged 18–85 years during the 2022–2023 season. Methods: A total of 144 adults were enrolled: group 1, aged 18–59 years (n = 124), and group 2, aged 60–85 years (n = 20). All received a quadrivalent inactivated subunit adjuvanted vaccine containing 5 μg of each influenza antigen and 500 μg of Azoximer bromide. IgG antibodies to vaccine strains were measured at baseline and days 30–32 using the hemagglutination inhibition assay. Participants were actively monitored for adverse events by telephone. Results: The Geometric Mean Fold Increase (GMFI) met the efficacy criteria in both age groups (≥2.5 for 18–59 years and ≥2.0 for 60–85 years), with no significant differences. The seroprotection rate reached accepted thresholds for most strains but was below criteria for B/Victoria in the 18–59 group (48%) and for B/Phuket in the 60–85 group (35%). Significant between-group differences were observed for B/Victoria (p = 0.01) and B/Phuket (p = 0.007). Seroconversion met criteria for all strains in younger adults, but for older adults, it was insufficient for B/Phuket (20%, below the ≥30% threshold; p = 0.05 vs. 18–59 years). Local reactions occurred in 24.2% and systemic in 11.3% of younger adults; in older adults, in 20% and 15%, respectively. All resolved spontaneously within 1–3 days. Conclusions: The quadrivalent adjuvanted influenza vaccine demonstrated acceptable immunogenicity and safety in adults aged 18–85 years despite potential post-COVID immune alterations.

1 January 2022 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
ATA.A. Tarasova
A.A. Tarasova
МKМikhail Petrovich Kostinov
Мikhail Petrovich Kostinov
MKMaria Kvasova
Maria Kvasova
Подходы к вакцинации против новой коронавирусной инфекции у пациентов с аутоиммунными воспалительными ревматическими заболеваниями